Abstract:Objective To study dendritic cells(DC)precursors that were mobilized into the pe- ripheral blood by injection of macrophage inflammation protein-1α(MIP-1α)and the anti-tumor effects induced by MIP-1αmobilized DC vaccine expressing tumor antigen in vivo.Methods 615 mice were in- jected with MIP-1αvia the tail vein.B220~-CD11c~+cells were sorted from the peripheral blood mononu- clear cells(MNCs)by FACS.The quantitive change of B220~-CD11c~+cells were compared among MNCs.Freshly isolated B220~-CD11c~+cells and B220~-CD11c~+cells cultured with mouse granulocyte- macrophage colony-stimulating factor(mGM-CSF),interleukin 4(IL-4),and mouse tumor necrosis factor-α(mTNF-α)were analyzed by phenotype analysis,and mixed lymphocyte reaction(MLR).For adenovi- ral(Ad)-mediated gene transduetion,cultured B220~-CD11c~+cells were incubated with Ad-melanoma antigen gene-3.B220~-CD11c~+cells pulsed mouse forestomach carcinoma cells(MFC)tumor lysate was used as control.To establish the solid tumor model,groups of 615 mice were injected with MFC cells sub- cutaneously in the abodminal wall.DC vaccines were immunized after the challenge of MFC cells,then the tumor size and the survival of mice which could detect the anti-tumor effects of DC vaccines were ob- served.Results B220~-CD11c~+cells were increased in the circulation 8 h after MIP-1αinjection, then gradually reached a peak level 48 h after injection,accounting for(13.68±0.95)% among MNCs. Freshly isolated B220~-CD11c~+cells did not show the characters of mature DC,while cultured B220~- CD11c~+cells were phenotyically identical to typical DC and gained the capacity to stimulate allogeneie T cells.These MIP-1αmobilized DCs were transduced with Ad-MAGE-3,which were prepared for DC vac- cines expressing tumor antigen.Five days after the challenge of MFC cells,mice were subsequently injected with DC vaccines.The.tumor size in the experimental group was much smaller than that in the control groups 27 days after the challenge.Kaplan-Meier survival curves revealed that the survival of the mice in the experimental group was much longer than that in the control groups(P<0.01).Conclusion B220~- CD11c~+DC precursors were rapidly accumulated in the peripheral blood after injection of MIP-1αin mice,which could further differentiate into mature DCs.These MIP-1αmobilized DCs,when transduced with MAGE-3 gene,could generate therapeutic anti-tumor effects on MFC cells loading mice in vivo.The efficiency of anti-tumor immunity induced by MIP-1αmobilized DCs expressing tumor antigen were much more potent than MIP-1αmobilized DCs pulsed MFC cells tumor lysate.

Research on MUC1 Antigen-specific Cytotoxic T Lymphocytes for Breast Cancer

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Anti-colonic Cancer Effect in Vitro of MUC1 Specific CTLs Induced by MUC1 Core Peptide Tandem Repeats Gene-Modified Dendritic Cells Via Lentiviral Transduction

The immunological investigation for anti-tumor roles of MUC1 vaccine in the bladder cancer

Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.

Anti-gastric carcinoma efficacy of gene modified dendritic cell vaccine recruited by macrophage inflammation protein-1

MUC1/Y plasmids as tumor vaccine in the experimental study of anti-tumor roles in the bladder cancer

[Study of the Cytotoxity Against Human Hepatocellular Carcinoma Cells Induced by the MAGE-1 Gene Modified Dendritic Cells].

[Dendritic Cells Infected by Recombinant Adeno-Associated Virus with CEA Gene to Induce Antigen-Specific CTL Response to CD44(+)CD24(-/low) Cells from MCF-7 Breast Cancer Cell Line].

The anti-tumor immune response of specific cytotoxic T lymphocytes induced by breast cancer stem cells RNA-DCs vaccine

Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit

A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice.

In vitro anti-tumor effect of cytotoxicity T lymphocytes activated by dendritic cells loaded with freeze-thaw ovarian carcinoma antigen

The Effect of Different Immunization Cycles of a Recombinant Mucin1-Maltose-Binding Protein Vaccine on T Cell Responses to B16-MUC1 Melanoma in Mice

Generation of CTL Responses Against Pancreatic Cancer in Vitro Using Dendritic Cells Co-Transfected with MUC4 and Survivin RNA.

Recombinant MUC1-MBP fusion protein combined with CpG2006 vaccine induces antigen-specific CTL responses through cDC1-mediated cross-priming mainly regulated by type I IFN signaling in mice

Anti-tumor effect of the antigen specific CTLs induced by dendritic cells transfected with total RNA of lung adenocarcinoma cell in vivo

Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model

MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide

Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles

Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine